{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:43:37Z","timestamp":1794861817594,"version":"4.9.1"},"reference-count":104,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are commercially available, and, in many cases, a lack of randomized clinical trial data makes selection of the optimal treatment for each patient challenging. Additionally, many patients continue to receive chemoimmunotherapy in the United States, suggesting a gap between guidelines and real-world practice. The Lymphoma Research Foundation convened a workshop comprising a panel of CLL\/SLL experts in the United States to develop consensus recommendations for selection and sequencing of therapies for patients with CLL\/SLL in the United States. Herein, the recommendations are compiled for use as a practical clinical guide for treating providers caring for patients with CLL\/SLL, which complement existing guidelines by providing a nuanced discussion relating how our panel of CLL\/SLL experts in the United States care for patients in a real-world environment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014474","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T17:02:07Z","timestamp":1732035727000},"page":"1213-1229","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-6819","authenticated-orcid":false,"given":"Jacob D.","family":"Soumerai","sequence":"first","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-5535","authenticated-orcid":false,"given":"Jacqueline","family":"Barrientos","sequence":"additional","affiliation":[{"name":"2Mount Sinai Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye","family":"Ahn","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Coombs","sequence":"additional","affiliation":[{"name":"4University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Gladstone","sequence":"additional","affiliation":[{"name":"5Northwell Health Cancer Institute, New Hyde Park, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hoffman","sequence":"additional","affiliation":[{"name":"6University of Kansas Cancer Center, Overland Park, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kittai","sequence":"additional","affiliation":[{"name":"7Mount Sinai Tisch Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Jacobs","sequence":"additional","affiliation":[{"name":"8Wake Forest Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lipsky","sequence":"additional","affiliation":[{"name":"9Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish","family":"Patel","sequence":"additional","affiliation":[{"name":"10Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Rhodes","sequence":"additional","affiliation":[{"name":"11Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Skarbnik","sequence":"additional","affiliation":[{"name":"12Novant Health Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-4802","authenticated-orcid":false,"given":"Meghan","family":"Thompson","sequence":"additional","affiliation":[{"name":"13Memorial Sloan Kettering Cancer Institute, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ermann","sequence":"additional","affiliation":[{"name":"14University of Utah Huntsman Cancer Institute, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8433-3360","authenticated-orcid":false,"given":"Patrick","family":"Reville","sequence":"additional","affiliation":[{"name":"15MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Shah","sequence":"additional","affiliation":[{"name":"14University of Utah Huntsman Cancer Institute, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9188-5008","authenticated-orcid":false,"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[{"name":"16Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"3","key":"2025032513471192800_bib1","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1093\/oncolo\/oyad324","article-title":"Treatment patterns, healthcare resource utilization, and costs of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the US","volume":"29","author":"Yang","year":"2024","journal-title":"Oncol"},{"issue":"suppl 1","key":"2025032513471192800_bib2","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1182\/blood-2022-163797","article-title":"Shift in first-line therapies for United States Veterans Health Administration (VHA) patients with chronic lymphocytic leukemia (CLL) from 2014 to 2021","volume":"140","author":"Lucero","year":"2022","journal-title":"Blood"},{"issue":"25","key":"2025032513471192800_bib3","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2025032513471192800_bib4","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on chronic lymphocytic leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2025032513471192800_bib5","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/leu.2017.246","article-title":"Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group","volume":"31","author":"Hoechstetter","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2025032513471192800_bib6","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2025032513471192800_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"key":"2025032513471192800_bib8","author":"Langerbeins","year":"13-17  2023"},{"key":"2025032513471192800_bib9","volume-title":"Venclexta (venetoclax). Package insert","year":"2022"},{"key":"2025032513471192800_bib10","volume-title":"Calquence (acalabrutinib). Package insert","year":"2017"},{"key":"2025032513471192800_bib11","volume-title":"Brukinsa (zanubrutinib). Package insert","year":"2024"},{"key":"2025032513471192800_bib12","volume-title":"Breyanzi (lisocabtagene maraleucel). Package insert","year":"2024"},{"issue":"11","key":"2025032513471192800_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clml.2019.07.004","article-title":"Long-term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia","volume":"19","author":"Kipps","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2025032513471192800_bib14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"2025032513471192800_bib15","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2023022564","article-title":"Reassessing the chronic lymphocytic leukemia international prognostic index in the era of targeted therapies","volume":"143","author":"Langerbeins","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025032513471192800_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.2020009813","article-title":"The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL","volume":"138","author":"Parikh","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2025032513471192800_bib17","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3026(19)30085-7","article-title":"Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations","volume":"6","author":"Soumerai","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025032513471192800_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/10428194.2023.2181656","article-title":"Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis","volume":"64","author":"Molica","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"2025032513471192800_bib19","author":"Wierda","year":"14  2024"},{"issue":"6","key":"2025032513471192800_bib20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.20.00979","article-title":"Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model","volume":"39","author":"Ahn","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"2025032513471192800_bib21","unstructured":"Testing early treatment for patients with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), EVOLVE CLL\/SLL study. ClinicalTrials.gov identifier: NCT042699022024. Updated 29 January 2025. Accessed 15 June 2024. https:\/\/clinicaltrials.gov\/study\/NCT04269902."},{"issue":"25","key":"2025032513471192800_bib22","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2025032513471192800_bib23","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"2025032513471192800_bib24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"2025032513471192800_bib25","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2025032513471192800_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032513471192800_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2025032513471192800_bib28","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032513471192800_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025032513471192800_bib30","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"15","key":"2025032513471192800_bib31","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025032513471192800_bib32","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"10232","key":"2025032513471192800_bib33","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"2025032513471192800_bib34","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"23","key":"2025032513471192800_bib35","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2025032513471192800_bib36","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025032513471192800_bib37","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"19","key":"2025032513471192800_bib38","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025032513471192800_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"2025032513471192800_bib40","unstructured":"National Library of Medicine. National Center for Biotechnology Information. A\u00a0study in previously untreated chronic lymphocytic leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy. ClinicalTrials.gov identifier: NCT03406156. Updated 6 August 2024. Accessed 15 June 2024. https:\/\/clinicaltrials.gov\/study\/NCT03406156."},{"issue":"7","key":"2025032513471192800_bib41","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"31","key":"2025032513471192800_bib42","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025032513471192800_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2025032513471192800_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025032513471192800_bib45","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2025032513471192800_bib46","first-page":"121","article-title":"Six-year update of the ELEVATE-TN study on acalabrutinib","volume":"22","author":"Sharman","year":"2024","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"2025032513471192800_bib47","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jha2.78","article-title":"Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL","volume":"1","author":"Agrawal","year":"2020","journal-title":"EJHaem"},{"issue":"1","key":"2025032513471192800_bib48","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.17105","article-title":"Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma","volume":"192","author":"Herishanu","year":"2021","journal-title":"Br J Haematol"},{"issue":"22","key":"2025032513471192800_bib49","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1182\/bloodadvances.2023010879","article-title":"Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL","volume":"7","author":"Tam","year":"2023","journal-title":"Blood Adv"},{"key":"2025032513471192800_bib50","volume-title":"Imbruvica (ibrutinib). Package insert","year":"2023"},{"issue":"6","key":"2025032513471192800_bib51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032513471192800_bib52","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1161\/STROKEAHA.120.033033","article-title":"Dual antiplatelet therapy versus aspirin in patients with stroke or transient ischemic attack: meta-analysis of randomized controlled trials","volume":"52","author":"Bhatia","year":"2021","journal-title":"Stroke"},{"issue":"14","key":"2025032513471192800_bib53","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1080\/10428194.2023.2254876","article-title":"Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes","volume":"64","author":"Redd","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025032513471192800_bib54","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"18","key":"2025032513471192800_bib55","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2025032513471192800_bib56","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"2025032513471192800_bib57","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"9","key":"2025032513471192800_bib58","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2025032513471192800_bib59","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032513471192800_bib60","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2025032513471192800_bib61","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III trial E2997","volume":"25","author":"Grever","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2025032513471192800_bib62","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"issue":"26","key":"2025032513471192800_bib63","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2025032513471192800_bib64","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2025032513471192800_bib65","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials","volume":"196","author":"Allan","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"2025032513471192800_bib66","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion","volume":"106","author":"Tam","year":"2021","journal-title":"Haematologica"},{"issue":"16","key":"2025032513471192800_bib67","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2025032513471192800_bib68","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025032513471192800_bib69","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"2025032513471192800_bib70","first-page":"2143","article-title":"Venetoclax-rituximab in chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025032513471192800_bib71","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"2025032513471192800_bib72","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/10428194.2024.2310144","article-title":"Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"65","author":"Lei","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025032513471192800_bib73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025032513471192800_bib74","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/bloodadvances.2023011741","article-title":"Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia","volume":"8","author":"Stilgenbauer","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"2025032513471192800_bib75","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"2025032513471192800_bib76","author":"Goede","year":"14  2018"},{"issue":"11","key":"2025032513471192800_bib77","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2020-0388","article-title":"Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia","volume":"25","author":"Hampel","year":"2020","journal-title":"Oncol"},{"key":"2025032513471192800_bib78","author":"Rawstron","year":"14  2023"},{"issue":"8","key":"2025032513471192800_bib79","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025032513471192800_bib80","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10232","key":"2025032513471192800_bib81","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(20)30372-X","article-title":"Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia","volume":"395","author":"Davids","year":"2020","journal-title":"Lancet"},{"issue":"31","key":"2025032513471192800_bib82","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2025032513471192800_bib83","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025032513471192800_bib84","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2025032513471192800_bib85","volume-title":"Jaypirca (pirtobrutinib). Package insert","year":"2023"},{"issue":"9","key":"2025032513471192800_bib86","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2025032513471192800_bib87","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2025032513471192800_bib88","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"2025032513471192800_bib89","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2025032513471192800_bib90","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"2025032513471192800_bib91","author":"Cramer","year":"14  2022"},{"key":"2025032513471192800_bib92","unstructured":"National Library of Medicine. National Center for Biotechnology Information. Study to assess change in disease activity and adverse events of oral venetoclax with intravenous (IV) obinutuzumab in adult participants with recurring chronic lymphocytic leukemia (CLL) (ReVenG). ClinicalTrials.gov identifier: NCT04895436. Updated 24 December 2024. Accessed 27 December 2024. https:\/\/clinicaltrials.gov\/study\/NCT04895436."},{"key":"2025032513471192800_bib93","author":"Wierda","year":"29  2024"},{"key":"2025032513471192800_bib94","author":"Woyach","year":"9  2023"},{"issue":"10402","key":"2025032513471192800_bib95","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"2025032513471192800_bib96","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025032513471192800_bib97","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2025032513471192800_bib98","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2025032513471192800_bib99","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2025032513471192800_bib100","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutre","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025032513471192800_bib101","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41409-023-01955-z","article-title":"The European landscape on allogeneic haematopoeietic cell transplantation in chronic lymphocytic leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT","volume":"58","author":"Tournilhac","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2025032513471192800_bib102","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2025032513471192800_bib103","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bbmt.2019.11.008","article-title":"Allogeneic haploidentical blood or marrow transplantation with post-transplantation cyclophosphamide in chronic lymphocytic leukemia","volume":"26","author":"Paul","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2025032513471192800_bib104","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1213\/2358713\/blooda_adv-2024-014474-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1213\/2358713\/blooda_adv-2024-014474-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T18:00:34Z","timestamp":1742925634000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/5\/1213\/526014\/Consensus-recommendations-from-the-2024-Lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":104,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014474","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]}}}